MB-dNPM1-TCR.1 not checked

Miltenyi Biomedicine GmbH

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
Tested for
Leukemia, Myeloid, Acute
Main trialPhase 1/2
“The goal of this Phase I/II, single arm, prospective, open label, dose escalation trial is to assess safety, feasibility and efficacy of ex vivo expanded autologous T cells genetically modified to express a T cell receptor (TCR) specific for dNPM1 peptides restricted to human leukocyte antigen (HLA) A\*02:01 in patients with relapsed or refractory AML.”In the company’s words, NCT06424340 on ClinicalTrials.gov

Other drugs for Leukemia, Myeloid, Acute

All 140 drugs for Leukemia, Myeloid, Acute

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Jun 2028 MB-dNPM1-TCR.1 in Relapsed/Refractory AML
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MB-dNPM1-TCR.1

Following is part of Solo: you see every change to MB-dNPM1-TCR.1 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in